Skip to content

MicroRNA-126 and Its Target VCAM-1Dermatitis to Nickel

Alteration of the microRNA-126 Expression: a Possible Mechanism in Allergic Contact Dermatitis to Nickel

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04365140
Enrollment
15
Registered
2020-04-28
Start date
2019-03-01
Completion date
2019-11-30
Last updated
2020-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic Contact Dermatitis

Keywords

allergic contact dermatitis, nickel, microRNAs, VCAM-1

Brief summary

Background. Allergic Contact Dermatitis (ACD) is an inflammatory skin disease mediated by direct contact with allergens as nickel, the most common allergen, that may be related with epigenetic changes. Objective. Evaluate the miR-126 expression and its target VCAM-1, in the skin of patients with ACD to nickel. Methods. Fifteen patients with positive patch test to nickel were included, and the expression of miR-126 and VCAM-1 was evaluated by RT-qPCR.

Detailed description

Patients that went to the dermatology and outpatient department of the Central Hospital Dr. Ignacio Morones Prieto , with a suspected diagnosis of nickel allergic contact dermatitis, were invited to participate in this study. Later, the objective and methodology of the study were explained to them, as well as the advantages of participating and the possible undesirable effects. All patients signed the informed consent previous perfom the medical history. After, the epicutaneous patch test was performed, and patients were divided according to the result them. Finally, under local anesthesia, two 3-mm punch biopsies, from lesional (positive parch test site) and adjacent non lesional skin, 10 cm apart, were performed. Tissues for reverse transcriptase real-time polymerase chain reaction (RT-qPCR) analyses were stored frozen in sterile tubes at 80ºC until processing

Interventions

None listed

Sponsors

Universidad Autonoma de San Luis Potosí
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* 18 years of age and older * Epicutaneous Patch Test positive to Nickel * without previous treatment within the previous 4 weeks

Exclusion criteria

* Pregnancy * nursing * menopause * consumption of any type of drugs (including anti-inflammatories and hormonal treatments) within the previous 2 months * coexistence of other dermatoses conditions

Design outcomes

Primary

MeasureTime frameDescription
Expression of miR-1269 monthsRelative expression of the miR-126 on skin biopsies from ACD patients

Countries

Mexico

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026